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Purpose: Stroke prevention in patients with atrial fibrillation (AF) is influenced by many factors. Using a contemporary registry, 
we evaluated variables associated with the use of warfarin or direct oral anticoagulants (OACs).
Materials and Methods: In the prospective multicenter CODE-AF registry, 10529 patients with AF were evaluated. Multivariate 
analyses were performed to identify variables associated with the use of anticoagulants.
Results: The mean age of the patients was 66.9±14.4 years, and 64.9% were men. The mean CHA2DS2-VASc and HAS-BLED scores 
were 2.6±1.7 and 1.8±1.1, respectively. In patients with high stroke risk (CHA2DS2-VASc ≥2), OACs were used in 83.2%, including di-
rect OAC in 68.8%. The most important factors for non-OAC treatment were end-stage renal disease [odds ratio (OR) 0.27; 95% 
confidence interval (CI): 0.19–0.40], myocardial infarct (OR 0.53; 95% CI: 0.40–0.72), and major bleeding (OR 0.57; 95% CI: 0.39–
0.84). Female sex (OR 1.40; 95% CI: 1.21–1.61), cancer (OR 1.78; 95% CI: 1.38–2.29), and smoking (OR 1.60; 95% CI: 1.15–2.24) were 
factors favoring direct OAC use over warfarin. Among patients receiving OACs, the rate of combined antiplatelet agents was 7.8%. 
However, 73.6% of patients did not have any indication for a combination of antiplatelet agents.
Conclusion: Renal disease and history of valvular heart disease were associated with warfarin use, while cancer and smoking sta-
tus were associated with direct OAC use in high stroke risk patients. The combination of antiplatelet agents with OAC was pre-
scribed in 73.6% of patients without definite indications recommended by guidelines.
Key Words:  Atrial fibrillation, anticoagulation, pattern, determinant
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: August 6, 2019   Revised: December 27, 2019   Accepted: January 9, 2020
Corresponding author: Boyoung Joung, MD, PhD, Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodae-
mun-gu, Seoul 03722, Korea.
Tel: 82-2-2228-8460, Fax: 82-2-393-2041, E-mail: cby6908@yuhs.ac
*Hyun Su Ha and Joongmin Kim contributed equally to this work.
•The authors have no potential conflicts of interest to disclose.
© Copyright: Yonsei University College of Medicine 2020
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Yonsei Med J 2020 Feb;61(2):120-128
https://doi.org/10.3349/ymj.2020.61.2.120
121
Hyun Su Ha, et al.
https://doi.org/10.3349/ymj.2020.61.2.120
INTRODUCTION
Atrial fibrillation (AF) is the most commonly sustained cardiac 
arrhythmia among the general population1-5 and is related to a 
5-fold increase in stroke risk.2,5,6 Preventing stroke is the prin-
cipal management in AF patients.7 Warfarin has been used for 
several decades as the mainstay of oral anticoagulants (OACs) 
and to reduce the relative risk of stroke in AF patients by 64% 
and all-cause mortality by 26%, compared to that in control 
groups.8,9 Direct oral anticoagulants (DOACs) have been shown 
to be as safe and effective as warfarin in large randomized con-
trolled trials,10 with lower incidences of intracranial hemor-
rhage. Indeed, DOACs also have several potential advantages 
over warfarin, including no need for routine coagulation mon-
itoring11 and fewer drug–drug and food–drug interactions.12 
Current guidelines suggest preferential use of DOACs in patients 
with nonvalvular AF and risk of thromboembolic events.5,13,14 
Nevertheless, both economical and medical reasons have lim-
ited the use of DOAC. 
Recent guidelines for AF patients undergoing percutaneous 
coronary intervention or acute coronary syndrome recommend 
short-term use of triple antithrombotic agents (TAT; OAC+ 
P2Y12 inhibitor+aspirin), 1-year dual antithrombotic agents (DAT, 
OAC+P2Y12 inhibitor or aspirin), and OAC alone for 1 year after 
percutaneous coronary intervention. However, the usage of 
TAT, DAT, or dual antiplatelet agents (DAP) is popular in many 
patients with AF.15,16 
Large cohort data showing contemporary anticoagulant us-
age patterns are still lacking. This study examined the anti-
thrombotic agent usage patterns and identified factors related 
to the use of DOACs or antiplatelet agents in a modern, pro-
spective, multicenter AF registry.
MATERIALS AND METHODS
Study design and centers 
The study design of the COmparison study of Drugs for symp-
tom control and complication prEvention of Atrial Fibrillation 
(CODE-AF) has been described in a previous study.17 Briefly, 
the CODE-AF registry is a prospective, multicenter, observa-
tional study of AF patients >18 years at 18 tertiary centers, in-
cluding all geographical regions of Korea.17 The study enroll-
ment period was from June 2016 to May 2019. 
The primary aim of the CODE-AF registry was to assess the 
outcomes of medical treatments, such as rate or rhythm con-
trol treatments, and anticoagulation.17 The secondary aim of 
the registry was to document the clinical epidemiology of AF 
patients and the diagnostic and therapeutic courses, such as 
the organization of AF management programs, applied in these 
patients and their clinical outcomes.17 The Korea Heart Rhythm 
Society designed and coordinated this registry.17 Data are en-
tered in a common electronic database that limits inconsisten-
cies and errors and provides online help for key variables.17 The 
study provided informed consent for inclusion in all patients 
and was approved by the ethics committee of each center. 
This study was registered at ClinicalTrials.gov (NCT02786095). 
The study was approved by the ethics committee of Severance 
Hospital (4-2016-0105).
Patients
Over the inclusion period, each center enrolled patients with 
AF attending the outpatient clinic and those hospitalized over 
the same period for AF. This registry excluded patients with 
moderate to severe mitral stenosis and a history of valve sur-
gery, which are indications of warfarin use. Also, patients with 
deep vein thrombosis or pulmonary embolism were not in-
cluded in the registry. From 10779 enrolled patients in the reg-
istry, patients with missing warfarin or DOAC usage data (n= 
47) and patients who switched OAC from warfarin to DOAC or 
vice versa (n=203) were excluded. After exclusion, a total of 
10529 patients were analyzed. Data collection was performed 
according to the same criteria and was usually performed by 
personnel who were not going to be associated with clinical 
activity in the project. Congestive heart failure/left ventricular 
dysfunction, hypertension, age ≥75 years (doubled), diabetes, 
stroke (doubled)–vascular disease, 65–74 years of age, and sex 
category (female) [CHA2DS2-VASc] score and hypertension, 
abnormal renal/liver function, stroke, bleeding history or pre-
disposition, labile international normalized ratio, older adult, 
and drugs/alcohol concomitantly (HAS-BLED) score were cal-
culated for all patients with non-valvular AF. A follow-up visit 
was scheduled every 6 months, either by personal interview or 
telephone contact. 
Anticoagulation
Patients with low stroke risk generally are not recommended 
antithrombotic therapy, while patients with high stroke risk 
(i.e., CHA2DS2-VASc score ≥1 for men and ≥2 for women) are 
likely to benefit from anticoagulation therapy.5,13,18 However, 
because the recommendation for patients with intermediate 
stroke risk remains controversial, guideline adherence was not 
evaluated in these patients.5,13,18
Statistical analysis 
All continuous variables were normally distributed, expressed 
as a mean±SD, and compared using Student’s t-test. Categori-
cal variables are expressed as numbers (percentages) and were 
compared between patients under warfarin or DOAC treat-
ment using a χ-squared test or Fisher exact test, as appropri-
ate. Multivariable logistic regression was performed to identify 
factors associated with warfarin versus DOAC. The outcome 
of interest was binary (warfarin or DOAC; OAC or non-OAC; 
OAC with or without antiplatelet agent). Logistic regression 
was performed by a backward conditional test. The significance 
threshold for inclusion in the model was 0.05. Candidate vari-
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ables were chosen from previous studies and experience. Re-
sults are presented as an odds ratio (OR) and 95% confidence 
interval (CI). All p-values were two tailed, and values less than 
0.05 were considered statistically significant. All statistical 
analyses were performed using the SPSS software (version 
25.0; IBM Corp., Armonk, NY, USA).
RESULTS 
Baseline characteristics
A total of 10529 patients with AF were analyzed. The mean age 
was 66.9±14.4 years, and 6833 (64.9%) of the patients were men. 
Mean CHA2DS2-VASc and HAS-BLED scores were 2.6±1.7 and 
1.8±1.1, respectively. OAC was used in 7409 (70.4%) patients: 
warfarin in 1556 (14.8%); and DOAC in 5853 (55.6%). Among 
patients with DOAC use, 1400 (23.9%) patients were treated with 
dabigatran, 1310 (22.4%) with rivaroxaban, 2086 (35.6%) with 
apixaban, and 1080 (18.5%) with edoxaban. 
Table 1 shows the comparison of baseline characteristics 
stratified by anticoagulant treatment. Compared to patients 
using warfarin, those using DOAC were older and had higher 
rates of arterial hypertension, diabetes mellitus, cancer, and a 
history of cerebrovascular disease. Mean CHA2DS2-VASc score 
was 2.6±1.7 in patients treated with warfarin and 3.1±1.5 in pa-
tients treated with DOAC (p<0.001).
Anticoagulant treatment strategies according to 
stroke and bleeding risk
Fig. 1 shows anticoagulant usage patterns in different CHA2DS2- 
VASc score groups. In patients with high stroke risk (CHA2DS2-
VASc ≥2), OAC was used in 83.2%, including 68.8% who re-
ceived DOAC. In patients with low to intermediate stroke risk 
(CHA2DS2-VASc <2), OAC was used in 37.9%, including 22.0% 
who received DOAC. Patients at high stroke risk were more 
prone to be treated with DOAC than warfarin, compared to the 
Table 1. Baseline Characteristics of Patients
Variables Overall (n=10529) None (n=3120) Warfarin (n=1556) DOAC (n=5853) p value
Male 6833 (64.9) 2314 (74.2) 1076 (69.2) 3443 (58.8) <0.001
Age (yr) 66.9±14.4 61.3±20.0 67.9±12.9 69.6±9.8 <0.001
Weight (kg) 66.9±11.8 68.3±11.8 66.8±11.9 66.2±11.8 <0.001
BMI (kg/m2) 24.7±3.4 24.5±3.2 24.6±3.5 24.8±3.4 <0.001
Type of AF
Paroxysmal AF 6815 (64.7) 2375 (76.4) 962 (61.9) 3478 (59.5) <0.001
Persistent/permanent AF 3668 (34.8) 728 (23.3) 592 (38.0) 2348 (40.1) <0.001
CHA2DS2-VASc 2.6±1.7 1.6±1.5 2.6±1.7 3.1±1.5 <0.001
HAS-BLED 1.8±1.1 1.4±1.1 2.4±1.2 1.8±0.9 <0.001
Heart failure 1026 (9.7) 152 (4.9) 186 (12.0) 688 (11.8) <0.001
Hypertension 6848 (65.0) 1575 (50.5) 992 (63.8) 4281 (73.1) <0.001
Diabetes mellitus 2596 (24.7) 420 (13.5) 423 (27.2) 1753 (30.0) <0.001
Dyslipidemia 3406 (32.3) 2245 (72.7) 1022 (66.2) 3777 (64.9) <0.001
History of stroke/TIA 1508 (14.3) 201 (6.4) 219 (14.1) 1088 (18.6) <0.001
History of MI 278 (2.6) 73 (2.3) 50 (3.2) 155 (2.6) 0.214
History of PAD 540 (5.1) 126 (4.0) 81 (5.2) 333 (5.7) 0.003
History of VHD 941 (8.9) 157 (5.0) 214 (13.8) 570 (9.7) <0.001
CKD 989 (9.4) 234 (7.5) 269 (17.3) 486 (8.3) <0.001
ESRD 168 (1.6) 83 (2.7) 75 (4.8) 10 (0.2) <0.001
Cancer 1011 (9.6) 311 (10.0) 103 (1.0) 597 (5.7) <0.001
History of bleeding 799 (7.6) 218 (7.0) 133 (8.6) 488 (7.7) 0.166
Aspirin 1667 (15.8) 1262 (41.3) 134 (8.8) 271 (4.7) <0.001
Clopidogrel 636 (6.0) 333 (10.9) 69 (4.5) 234 (4.1) <0.001
Dabigatran - - - 1400 (23.9) -
Rivaroxaban - - - 1310 (22.4) -
Apixaban - - - 2086 (35.6) -
Edoxaban - - - 1080 (18.5) -
AF, atrial fibrillation; BMI, body mass index; CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/tran-
sient ischemic attack, vascular disease, age 65 to 74 years, female; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposi-
tion, labile international normalized ratio, elderly, concomitant drugs/alcohol; TIA, transient ischemic attack; MI, myocardial infarct; PAD, peripheral artery disease; 
VHD, valvular heart disease; CKD, chronic kidney disease; ESRD, end-stage renal disease.
Data are presented as mean±SD or number (%).
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low- and intermediate-risk groups (p<0.001). 
Fig. 2 shows anticoagulant usage patterns according to HAS-
BLED score grouping. Mean HAS-BLED score was 2.4±1.2 in 
patients treated with warfarin and 1.8±0.9 in patients under 
DOAC treatment. In patients with low and intermediate bleed-
ing risk (HAS-BLED score=0–2), OAC was used in 68.2%, in-
cluding 57.9% who received DOAC. In patients with high bleed-
ing risk (HAS-BLED score ≥3), OAC was used in 77.9%, including 
48.1% who received DOAC. Patients at low and intermediate 
risk of bleeding were more prone to be treated with DOAC than 
those at high risk of bleeding (p<0.001).
OAC vs. non-OAC treatment in all patients
In 7547 AF patients with high stroke risk, OAC was not used in 
16.8%, and antiplatelet was used in 8.8% among them. Aspirin, 
P2Y12 inhibitor, and aspirin plus P2Y12 inhibitor were used in 6.1, 
1.7, and 1.0% patients, respectively. Fig. 3 shows variables as-
sociated with OAC or non-OAC treatment in the CHA2DS2-VASc 
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Fig. 1. Method of stroke prevention in patients with AF according to CHA2DS2-VASc score. AF, atrial fibrillation; APT, antiplatelet therapy; DOAC, direct oral 
anticoagulant.
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score ≥2 groups. Compared to variables favoring non-OAC 
treatment, variables favoring OAC treatment were factors for 
calculating CHA2DS2-VASc score: age ≥75 (OR 1.60; 95% CI: 
1.40–1.83), history of valvular heart disease (OR 1.28; 95% CI: 
1.03–1.59), history of stroke/TIA (OR 1.51; 95% CI: 1.28–1.79), 
heart failure (OR 1.53; 95% CI: 1.24–1.88), and diabetes melli-
tus (OR 1.42; 95% CI: 1.23–1.63).
The four most important factors favoring non-OAC treatment 
were end-stage renal disease (ESRD) on dialysis (OR 0.27; 95% 
CI: 0.19–0.40), cancer (OR 0.67; 95% CI: 0.56–0.81), myocardi-
al infarct (OR 0.53; 95% CI: 0.40–0.72), and history of major 
bleeding (OR 0.57; 95% CI: 0.39–0.84).
DOAC vs. warfarin in patients with CHA2DS2-VASc ≥2
We analyzed variables favoring DOAC or warfarin in the CHA2DS2- 
VASc score ≥2 group. The three important variables favoring 
DOAC treatment were female sex (OR 1.40; 95% CI: 1.21–1.61), 
cancer (OR 1.78; 95% CI: 1.38–2.29), and smoking (OR 1.60; 95% 
CI: 1.15–2.24) (Fig. 4). Variables favoring warfarin were ESRD 
(OR 0.06; 95% CI 0.03–0.11), chronic kidney disease (CKD) (OR 
0.48; 95% CI 0.40–0.58), and history of valvular heart disease 
(OR 0.58; 95% CI 0.48–0.71) (Fig. 4). History of bleeding had no 
effect in determining the type of OAC. 
OAC vs. DAT or TAT 
In patients with CHA2DS2-VASc ≥2, antiplatelet agents were si-
multaneously used with OAC in 585 (7.8%) out of 7547 patients, 
including 433 (5.7%) who received DOAC and 152 (2.0%) with 
warfarin. However, 73.6% patients did not have any indication 
for the combination of antiplatelet agents, such as acute coro-
nary syndrome, percutaneous coronary artery disease, or high 
thrombotic coronary lesions.
Variables associated with OAC plus antiplatelet agents were 
history of myocardial infarct (OR 3.94; 95% CI: 2.73–5.67), his-
tory of peripheral artery disease (OR 3.09; 95% CI: 2.34–3.07), 
and dyslipidemia (OR 2.43; 95% CI: 2.01–2.94) (Fig. 5). 
DISCUSSION
Among AF patients at high risk of stroke, OAC was not adminis-
tered in 16.8% of patients. Turkish registry showed that 27.1% 
of patients who have CHA2DS2-VASc score ≥2 received no OAC 
therapy. The primary reasons for the lack of anticoagulant us-
age in patients with high stroke risk were physicians’ concerns 
for bleeding events and patient refusal.19 In our study, the four 
most important factors favoring non-OAC treatment were ESRD, 
history of myocardial infarct, history of major bleeding, and 
cancer. Second, among OAC patients, DOACs were used in 68.8%. 
Important factors favoring DOAC treatment were female, can-
cer, and smoking status. Finally, a combination of OAC and an-
tiplatelet agents was used in 7.8% patients, but without definite 
indication in most patients (73.6%). This result suggests that, 
while adherence to general OAC guidelines has improved, an-
tiplatelet agents are still being used against indication, thus ne-
cessitating improvement in the adherence to guidelines in Ko-
rean patients with AF.
The incidences of major bleeding and hemorrhagic stroke 
Age ≥75 1.60 (1.40–1.83), p<0.001
BMI   1.04 (1.02–1.05), p<0.001
History of MI   0.53 (0.40–0.72), p<0.001
History of VHD   1.28 (1.03–1.59), p=0.024
History of stroke/TIA   1.51 (1.28–1.79), p<0.001
ESRD on dialysis   0.27 (0.19–0.40), p=0.010
Cancer   0.67 (0.56–0.81), p<0.001
Heart failure   1.53 (1.24–1.88), p<0.001
DM   1.42 (1.23–1.63), p<0.001
Major bleeding   0.57 (0.39–0.84), p<0.001
Minor bleeding   0.79 (0.63–0.98), p=0.034
OR (95% CI)
0                                     0.5                                   1.0                                    1.5                                     2.0
Favoring non-OAC Favoring OAC
Fig. 3. Factors favoring OAC or non-OAC treatment in patients with CHA2DS2-VASc ≥2. OAC, oral anticoagulant; BMI, body mass index; MI, myocardial in-
farct; VHD, valvular heart disease; TIA, transient ischemic attack; ESRD, end-stage renal disease; DM, diabetes mellitus; OR, odds ratio; CI, confidence in-
terval.
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seem to be higher in patients under warfarin treatment. In large 
randomized controlled trials,10 patients treated with warfarin 
presented rates of 3.1–3.4%/year and 0.70–0.80%/year for major 
bleeding and hemorrhagic stroke, respectively. DOAC showed 
a significant reduction in hemorrhagic stroke of 0.23–0.49% and 
a similar reduction in major bleeding rate of 2.13–3.6%. Further-
more, DOAC was more frequently prescribed in patients with 
a history of major bleeding or hemorrhagic stroke. Table 2 
shows a summary of different AF registry results for variables 
favoring DOAC or warfarin. In a Danish registry, patients under 
DOAC treatment were female, older, and had higher prevalenc-
es of stroke, bleeding, and alcoholism. Similar to this study, the 
main factor associated with warfarin treatment was the pres-
ence of kidney disease, myocardial infarction, and congestive 
Female   1.40 (1.21–1.61), p<0.001
BMI   1.02 (1.00–1.04), p=0.028
History of VHD   0.58 (0.48–0.71), p<0.001 
CKD   0.48 (0.40–0.58), p<0.001
ESRD   0.06 (0.03–0.11), p<0.001
Cancer   1.78 (1.38–2.29), p<0.001
Smoking   1.60 (1.15–2.24), p=0.006
        Favoring warfarin                       Favoring DOAC
0                          0.5                        1.0                        1.5                        2.0                           2.5                     3.0
OR (95% CI)
Fig. 4. Factors favoring warfarin or DOAC in patients with CHA2DS2-VASc ≥2. DOAC, direct oral anticoagulant; BMI, body mass index; VHD, valvular heart 
disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; OR, odds ratio; CI, confidence interval.
Female   0.66  (0.54–0.80), p<0.001
History of MI   3.94 (2.73–5.67), p<0.001
History of PAD   3.09 (2.34–3.07), p<0.001 
History of stroke/TIA   1.47 (1.20–1.81), p<0.001
Dyslipidemia   2.43 (2.01–2.94), p<0.001
CKD   1.40 (1.10–1.80), p=0.007
Heart failure   1.38 (1.07–1.77), p=0.012
HTN   1.38 (1.07–1.77), p=0.012
DM   1.28 (1.06–1.55), p=0.010
Favoring OAC                                  Favoring OAC+antiplatelet
0                           1                           2                           3                           4                           5                           6
OR (95% CI)
Fig. 5. Factors favoring OAC plus antiplatelet in patients with CHA2DS2-VASc ≥2. OAC, oral anticoagulant; MI, myocardial infarct; PAD, peripheral arterial 
disease; TIA, transient ischemic attack; CKD, chronic kidney disease; HTN, hypertension; DM, diabetes mellitus; OR, odds ratio; CI, confidence interval.
Table 2. Summary of Atrial Fibrillation Registry for Variables Favoring Warfarin or DOAC
Study Registry name Number of data Favoring warfarin variables Favoring DOAC variables
Olesen, et al.20 Danish 18611 CKD, MI, HF
Older age, female, prior stroke history, bleeding history, 
  alcohol abuse
Moreno-Arribas, 
  et al.21 
FANTASIIA 
  (spanish)
1290 Malignancy, bradyarrhythmia
Major bleeding history, hemorrhagic stroke history, university 
  education, high diastolic blood pressure, higher eGFR
This study CODE-AF 10529
ESRD, CKD, history of valvular
  heart disease
Female, cancer, smoking history
DOAC, direct oral anticoagulant; CKD, chronic kidney disease; MI, myocardial infarct; HF, heart failure; eGFR, estimated glomerular filtration rate; ESRD, end-
stage renal disease.
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heart failure.20 In a Spanish study (FANTASIIA), patients under 
DOAC treatment had higher prevalences of hemorrhagic stroke 
and bleeding history, university education, and higher glomer-
ular filtration rate. Prescription of warfarin was higher in pa-
tients with history of cancer or bradyarrhythmias.21 A recent 
retrospective observational study reported that patients with 
greater bleeding and ischemic stroke risk were more likely to 
initiate warfarin, whereas in those at lower risk of bleeding, 
DOAC usage was more common.22
High-quality anticoagulation control with warfarin is associ-
ated with better efficacy and safety (with low stroke and bleed-
ing risks); thus, effective stroke prevention in various guide-
lines on OAC refer to the use of well-controlled warfarin [time 
in therapeutic range (TTR) ≥70%) or one of the DOACs.23 How-
ever, it is difficult to maintain optimal TTR in Asian patients with 
AF.24 
A cost-effectiveness study has demonstrated that DOACs are 
cost effective in Asian patients with AF.25 In this study, the us-
age rate and guideline adherence of OAC dramatically in-
creased, because of the increased use of DOAC (55.6%). Inter-
estingly, warfarin usage decreased more than that reported in 
a previous Korean study.1 Other studies reported a risk-treat-
ment paradox, in which OAC use decreased with an increasing 
stroke risk.26 However, this study showed that the rate of OAC 
use was consistently maintained, even in patients with high 
bleeding risk. 
TAT poses a higher bleeding risk than OAC or DAP alone.27,28 
Recent studies about DOAC showed that double antithrom-
botic therapy with OAC and a P2Y12 inhibitor is safer than triple 
antithrombotic therapy, including the use of warfarin.29,30 No-
tably, both the 2018 ESC guidelines and the 2019 ACC/AHA/
HRS guidelines for AF recommended DAT (COR IIa) as an al-
ternative to TAT to reduce bleeding risk, although this indica-
tion is currently only applied to patients at high bleeding risk 
in European guidelines.15,31,32 Therefore, the need for DOACs 
in combination with antiplatelet agents should be critically 
assessed, and the duration of combined therapy should be 
minimized. However, 73.6% patients did not have an indica-
tion for the combination of antiplatelet agents, such as acute 
coronary syndrome, percutaneous coronary artery disease, or 
high thrombotic coronary lesions. This result suggests that 
awareness regarding new guidelines is urgently required for 
Korean patients with AF.
The main limitation of our study is the nature of a transversal 
observational study. Our analysis of medication use focused 
on prescriptions filled in the first few months of the calendar 
year, and we were unable to ascertain longitudinal adherence. 
Secondly, patients are representative of a Korean population, 
and results may not be extrapolated to other populations. Fi-
nally, as all patients were enrolled from tertiary centers, the 
current registry is not free from referral bias. 
In conclusion, ESRD, history of myocardial infarct, and his-
tory of major bleeding were related to non-OAC treatment. Re-
nal disease and history of valvular heart disease were associat-
ed with warfarin usage, while female, cancer, and smoking status 
were associated with DOAC usage in patients at high risk of 
stroke. A combination of antiplatelet agents with OAC was pre-
scribed in 73.6% patients without definite indication recom-
mended by guidelines. This result suggests that, while adher-
ence to general OAC guidelines have improved, antiplatelet 
agents are still being used against indications, thus necessitat-
ing improvement in adherence to guidelines in Korean patients 
with AF. 
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